Equities

Definitive Healthcare Corp

DH:NSQ

Definitive Healthcare Corp

Actions
TechnologyTechnology
  • Price (USD)4.57
  • Today's Change0.17 / 3.86%
  • Shares traded735.55k
  • 1 Year change-36.35%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy4
Outperform0
Hold8
Sell1
Strong Sell0

Share price forecast in USD

The 9 analysts offering 12 month price targets for Definitive Healthcare Corp have a median target of 5.00, with a high estimate of 7.00 and a low estimate of 4.00. The median estimate represents a 9.41% increase from the last price of 4.57.
High53.2%7.00
Med9.4%5.00
Low-12.5%4.00

Earnings history & estimates in USD

On Nov 07, 2024, Definitive Healthcare Corp reported 3rd quarter 2024 earnings of 0.10 per share. This result exceeded the 0.08 consensus of the 12 analysts covering the company and exceeded last year's 3rd quarter results by 11.11%.
The next earnings announcement is expected on Feb 26, 2025.
Average growth rate+3.92%
Definitive Healthcare Corp reported annual 2023 earnings of 0.300 per share on Feb 28, 2024.
Average growth rate+93.00%
More ▼

Revenue history & estimates in USD

Definitive Healthcare Corp had 3rd quarter 2024 revenues of 62.70m. This bettered the 61.72m consensus of the 12 analysts covering the company. This was 5.91% above the prior year's 3rd quarter results.
Average growth rate-1.00%
Definitive Healthcare Corp had revenues for the full year 2023 of 251.42m. This was 12.92% above the prior year's results.
Average growth rate+23.46%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.